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Valorization
Beyond the scientific relevance of the thesis issued herein, the presented work 
describes an area of research that could be translated into a socially and economically 
relevant product. In Chapter 5, the disclosed cluster of small, drug-like molecules 
which act on the energy sensor AMPK could lead in the future to a new drug of interest 
in a number of diseases. 
A new drug to target AMPK in an innovative manner
Relevance & Target groups
As described in Chapter 2, AMPK is involved in a wide number of diseases, from 
cardiac diseases to cancer through diabetes. Over the years, this protein has emerged 
as a potential drug target in many of these fields and the area of research keeps 
expanding as novel AMPK downstream effects unravel. The most established domain in 
which AMPK beneficial targeting is known is type 2 diabetes. In contrast to type 1 
diabetes, type 2 diabetes is associated to obesity, physical inactivity, poor diet and age. 
Due to the change in lifestyle induced by worldwide economic development, more and 
more people are at risk of developing this condition [1]. According to the most recent 
estimations of the International Diabetes Federation, 382 millions of people suffer 
from diabetes worldwide and this number is predicted to have risen by 55% in 2035 if 
trends keep as they are. Beyond the direct risk associated with the disease, diabetes 
leads to many more health complications such as cardiovascular diseases and kidney 
failure. Logically, the costs in healthcare created by diabetes are enormous: as a 
consequence of undiagnosed diabetes alone, the healthcare costs in the USA were 
estimated to USD 18 billion for one year [1].
If only for its beneficial role in treatment of this metabolic disorder, AMPK is therefore 
well worth studying. Moreover, in the past decades, a few proteins in specific cellular 
pathways have emerged as responsible for age-related disease occurrence [2, 3]. To 
clarify, the mutation of these proteins in animal models can prolong their healthy 
lifespan significantly. For some of these targets such as those related to insulin/IGF1, 
certain mutations correlate with longevity in different human cohorts [2]. Although 
AMPK did not yet reach such a level of characterization, there is evidence to show that 
AMPK activation may also potentiate an increase of healthy lifespan [3].
Even though AMPK is involved in many pathways, studies using indirect or direct 
activators showed mostly beneficial effects without side-effects in a wide array of 
diseases [4]. Only in very specific cases of the fields of cancer and neurodegenerative 
disorders, the activation of AMPK sometimes led to worsening of the symptoms. 
Therefore, the targeting of AMPK is considered as generally safe with only cautions to 
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be taken under some conditions.
In summary, considering the high occurrence of diseases related to ageing or 
“modern” lifestyle that could benefit from AMPK activity, the development of bioactive 
compounds that target AMPK is of obvious relevance, both from social and economic 
points of view. 
Product & Innovation
Several methods to directly or indirectly activate AMPK with drug-like molecules 
have been described [5]. For direct targeting, three different methods exist that activate 
the protein through action on different aspects of AMPK regulation. In each of these 
categories, a high number of studies have led to the identification of many compounds 
with different structures. Unfortunately, to date, none of these molecules have reached 
the market, generally due to off-target effects or to poor absorption in the body. With 
regards to indirect activation of AMPK, different types of molecules mimic an energy 
stress within the cell they reach, thereby activating AMPK. Among these, several natural 
products and nutraceuticals, such as resveratrol or curcumin, were shown to activate 
AMPK [6]. More importantly, the most widely prescribed drug, metformin, also activates 
AMPK in an indirect manner [7]. This treatment against type 2 diabetes exerts its 
beneficial effects partly through AMPK. However this drug as well as all indirect AMPK 
activators has many other targets than AMPK. Therefore the search for a safe and 
efficient strategy to directly target the protein is still on-going.
In Chapter 5, we describe the identification of novel molecules that target AMPK in 
an innovative manner. Our primary aim in designing these compounds was not to 
directly modulate AMPK activity but rather AMPK effects: instead of influencing AMPK 
activity as other AMPK activators do, our compounds were selected for their ability to 
modify AMPK localization within the cell, and bring it away from the cellular store of 
glucose, glycogen. This change of localization should influence the protein partners 
that AMPK can find and thereby alters the outcome of AMPK activity. Unexpectedly, the 
compound, named 6469172, which had the strongest ability to change AMPK 
localization, also modulates AMPK activity. The precise mechanism that triggers this 
increase in activity is still unexplained at this stage, but still provoked glucose uptake 
in cells treated with 6469172. Therefore this compound shows promises for the 
treatment of type 2 diabetes where glucose needs to be taken up from the blood into 
cellular reserves.
In summary, the newly identified compound, 6469172, is the basis on which a new 
drug targeting AMPK could be developed. The mechanism of action which targets 
AMPK localization rather than directly its activity makes it an innovation in the field of 
AMPK targeting. Considering on one hand the interest that AMPK activators trigger for 
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their beneficial roles in many diseases and on the other hand the current lack of an 
efficient strategy to take advantage of AMPK effects, the compound 6469172 shows 
interesting potential for further development into a marketed product.
Schedule & Implementation
Despite its great interest for future applications, the compound 6469172 is still in a 
very early stage of a drug development. The data presented within this thesis establish 
the ability of 6469172 to change AMPK localization and to bind directly to one of the 
domain of this protein. Furthermore, the first tests show the change of AMPK activity 
induced by treatment with 6469172 and the resulting increase in glucose and fatty acid 
uptake. Although these data are encouraging, they are far from sufficient. As explained 
in Chapter 6, even though bioinformatics tools were used to filter out molecules that 
were unlikely to behave as drugs, many tests still need to be conducted to certify that 
our newly-found molecule meets the requirements regarding absorption, distribution, 
metabolism and excretion (ADME) once in the body [8]. Strict criteria regarding toxicity 
have also to be adhered to. Moreover, further levels of characterization, both in vivo and 
in vitro, have to be followed to assess the benefits that this molecule can trigger in 
disease conditions. Finally, the compound 6469172 together with other structurally-
related ones identified herein will serve to document structure-activity relationship 
studies, which will lead to the definition of another chemical structure with optimal 
characteristics in both ADME/toxicity and potency tests. This development phase is 
called hit-to-lead and is followed by lead optimization. After these stages, the final 
compounds enter clinical trials, which is again a very long and costly process.
Therefore, a long road still awaits 6469172 before the concept developed with this 
molecule can be translated into a commercial product. Generally, from the initial idea 
to the market launch, the development of a drug takes 12-15 years and costs more than 
one billion USD [8]. Our initial work brought us from initial idea to the beginning of the 
hit-to-lead phase, but the main costs remain ahead with the clinical trials to come. Even 
though the phases of early drug development are progressively taken over by academic 
groups or academic drug development centers, clinical trials remains the exclusive 
field of established pharmaceutical companies or their spin-off. In the case of 6469172, 
no patents were filled at this stage because the gathered data were considered to 
provide too little ground for a university to take the financial risk. However, discussions 
with pharmaceutical companies are planned to see how research could be carried on 
possibly with other undisclosed molecules.
In summary, the newly-identified compounds presented herein have some promising 
and innovative application lying ahead, even though the stage of development and 
characterization is still too early to really predict whether a commercial application 
could stem from them.
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